Coagulation activation in young survivors of myocardial infarction (MI) - A population-based case-control study

Thrombosis and Haemostasis

Volumn 92, Issue 1, 2004, Pages 178-184

  Brodin, Ellen ^a   Børvik, Trond ^a   Sandset, Per Morten ^b   Bønaa, Kaare H ^a   Nordøy, Arne ^a   Hansen, John Bjarne ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Ischaemic heart disease; Thrombin; Tissue factor pathway inhibitor (TFPI); Tissue factor factor VII

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 7A; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC ACID DERIVATIVE; THROMBIN ANTITHROMBIN COMPLEX; TISSUE FACTOR PATHWAY INHIBITOR; TRIACYLGLYCEROL;

ADULT; ANTIGEN DETECTION; ARTICLE; BLOOD CLOTTING; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY RISK; FEMALE; HEART INFARCTION; HEMOSTASIS; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; SURVIVAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 3543005942     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-11-0674     Document Type: Article

References (36)

1. Tremoli E, Camera M, Toschi V, et al. Tissue factor in atherosclerosis. Atherosclerosis 1999; 144: 273-83.
2. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndrome. N Engl J Med 1992; 326: 310-8.
3. Wilcox JN, Smith KM, Schwartz SM, et al. Localization of tissue factor in normal vessel and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-43.
4. Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-4.
5. Suefuji K, Ogawa H, Yasue H. Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J 1997; 134: 253-9.
6. Misumi K, Ogawa H, Yasue H. Comparison of plasma tissue factor levels in unstable and stable angina pectoris. Am J Cardiol 1998; 81: 22-6.
7. Broze GJ Jr., Warren LA, Novotny WF, et al. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action. Blood 1988; 71: 335-43.
8. Warn-Cramer BJ, Rao LVM, Maki SL, et al. Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: evidence for a two-step model of inhibition. Thromb Haemost 1988; 60: 453-6.
9. Van de Loo J, Annotation. Circulating factors of the haemostatic system as indicators of increased or reduced coronary risk. Br J Haematol 1995; 91: 777-82.
10. Bajaj MS, Kuppuswamy MN, Saito H, et al. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: Evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA 1990; 87: 8869-73.
11. Falciani M, Gori AM, Fedi S, et al. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischemic heart disease patients. Thromb Haemost 1998; 79: 495-9.
12. Nakagaki T, Foster DC, Berkner KL, et al. Initiation of the extrinsic pathway of blood coagulation: evidence for the tissue factor dependent auto activation of human coagulation factor VII. Biochemistry 1991; 30: 10819-24.
13. Carvalho de Sousa J, Azvedo J, Soria C, et al. Factor VII hyperactivity in acute myocardial thrombosis: a relation to the coagulation activation. Thromb Res 1988; 51: 165-73.
14. Miller GJ, Bauer KA, Barzegar S, et al. Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease. Thromb Haemost 1996; 75: 767-77.
15. Moor E, Silveira A, Hooft FV, et al. Coagulation factor VII mass and activity in young men with myocardial infarction at a young age. Role of plasma lipoproteins and factor VII genotype. Arterioscler Thromb Vasc Biol 1995; 15: 655-64.
16. Merlini PA, Bauer K, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 61-8.
17. Li YH, Teng JK, Tsai WC, et al. Prognostic significance of elevated haemostatic markers in patients with acute myocardial infarction. J Am Coll Cardiol 1999; 33: 1543-8.
18. Peternel P, Terbizan M, Tratar G, et al. Markers of haemostatic system activation during treatment of deep vein thrombosis with subcutaneous unfractionated or low molecular weight heparin. Thromb Res 2002; 105: 241-6.
19. Burstein M, Scholnick HR, Mofin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyamines. J Lipid Res 1970; 11: 583-95.
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifugation. Clin Chem 1972; 18: 499-502.
21. Sandset PM, Larsen ML, Abildgaard U, et al. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. Blood Coagul Fibrinolysis 1991; 2: 425-33.
22. Østergaard PB, Beck TC, Ørsted H, et al. An enzyme linked immunosorption assay for tissue factor pathway inhibitor. Thromb Res 1997; 87: 447-59.
23. Morrisey JH, Marci BG, Neuenschwander PF, et al. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-44.
24. Ottani F, Galvani M. Prognostic role of haemostatic markers in acute coronary syndrome patients. Clinica Chimica Acta 2001; 311: 33-9.
25. Danielsen R, Onundarson P, Thors H, et al. Activated and total coagulation factor VII, and fibrinogen in coronary artery disease. Scand Cardiovasc 1998; 32: 87-95.
26. Moor E, Silveira A, Hooft FV, et al. Coagulation factor VII mass and activity in young men with myocardial infarction at a young age. Arterioscler Thromb Vasc Biol 1995; 15: 655-64.
27. Cooper JA, Miller GJ, Bauer KA, et al. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation 2000; 102: 2816-22
28. Golino P. The inhibitors of the tissue factor: factor VII pathway. Thromb Res 2002; 106: 257-65.
29. Mesters RM, Mannucci PM, Coppola R, et al. Factor VIIa and antithrombin III activity during servere sepsis and septic shock in neutropenic patients. Blood 1996; 88: 881-6.
30. Rapaport SI, Rao LVM. The tissue factor pathway: How it has become a "prima ballerina". Thromb Haemost 1995; 74: 7-17.
31. Alums FE, Rao LVM, Rapaport SI. Regulation of factor VIIa/tissue factor functional activity in an umbilical vein model. Arterioscler Thromb Vasc Biol 1993; 13: 105-11.
32. Kawaguchi A, Miyao Y, Noguchi T, et al. Intravascular free tissue factor pathway inhibitor is inversely correlated with HDL cholesterol and postheparin lipoprotein lipase but proportional to apolipoprotein A-II. Arterioscler Thromb Vasc Biol 2000; 20: 251-8.
33. Saigo M, Abe S, Ogawa M, et al. Imbalance of plasminogen activator inhibitor -1/tissue plasminogen activator and tissue factor/tissue factor pathway inhibitor in young Japanese men with myocardial infarction. Thromb Haemost 2001; 86: 1197-203.
34. Hansen JB, Grimsgaard S, Huseby NE, et al. Serum lipids and regulation of tissue factor-induced coagulation in middle-aged men. Thromb Res 2001; 102: 3-13.
35. Hansen JB, Huseby NE, Sandset PM, et al. Tissue factor pathway inhibitor and lipoproteins: evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb Vasc Biol 1994; 14; 223-9.
36. Kokawa T, Abumiya T, Kimura T, et al. Tissue factor pathway inhibitor activity in human plasma. Measurement of lipoprotein-associated and free forms in hyperlipidemia. Arterioscler Thromb Vasc Biol 1995; 15: 504-10.